Structure, activity, and immune (T and B cell) recognition of botulinum neurotoxins

Critical Reviews in Immunology

Volumn 19, Issue 3, 1999, Pages 219-260

  Atassi, M Zouhair ^a   Oshima, Minako ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Antibodies; Botulinum neurotoxin; Epitopes; Synthetic peptides; T cells

Indexed keywords

BOTULINUM TOXIN A; EPITOPE; INACTIVATED VACCINE; NEUROTRANSMITTER;

ANTIGEN RECOGNITION; B LYMPHOCYTE; BOTULISM; CARBOXY TERMINAL SEQUENCE; CROSS REACTION; GENE STRUCTURE; HUMAN; MOUSE; NEUROTRANSMITTER RELEASE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

AMINO ACID SEQUENCE; ANIMALS; B-LYMPHOCYTES; BOTULINUM TOXINS; HUMANS; IMMUNITY, CELLULAR; MOLECULAR SEQUENCE DATA; POISONING; SEQUENCE HOMOLOGY, AMINO ACID; T-LYMPHOCYTES;

EID: 0033023671     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (271)

1. Van Ermengem, E., Uber einen neuen anaeroben Bacillus und seine Beziehungen zum Botulismus, Z. Hyg. Infektionskr., 26, 1-56, 1897.
2. Van Ermengem, E., Contributions a l'etude des intoxications alimentaires, Arch. Int. Pharmacodyn., 3, 213-350, 499-601, 1897.
3. Aguilera, J., Ahnert-Hilger, G., Bigalke, H., DasGupta, B. R., Dolly, O., Habermann, E., Halpern, J., van Heyningen, S., Middlebrook, J., Mochida, S., Montecucco, C., Niemann, H., Oguma, K., Popoff, M., Poulain, B., Simpson, L., Shone, C. C., Thompson, D. E., Weller, U., Wellhoner, H. H., and Whelan, S. M., Clostridial neurotoxins-proposal of a common nomenclature, FEMS Microbiol. Lett., 90, 99-100, 1992.
4. Brooks, V. B., An intracellular study of the action of repetitive nerve volleys and of botulinum toxin on miniature end-plate potentials, J. Physiol., 134, 264-277, 1956.
5. Sakaguchi, G., Ohishi, I., and Kozaki, S., Botulism-structure and chemistry of botulinum, in Handbook of Natural Toxins, Hardgree, M. C. and Tu, A. T., Eds., vol. 4, Marcel Dekker, New York, 1988, 191-216.
6. Cherington, M., Clinical spectrum of botulism, Muscle Nerve, 6, 701-710, 1998.
7. Tacket, C. O. and Rogawski, M. A., The disease and the treatment of botulism, in Botulinum Neurotoxin and Tetanus Toxin, Simpson, L. L., Ed., Academic Press, New York, 1989, 351-373.
8. Cochran, D. P. and Appleton, R. E., Infant botulism - is it that rare? Developmental Med. Child Neurol., 3, 274-278, 1995.
9. Llamana, C., The most poisonous poison, Science, 130, 763-772, 1959.
10. Middlebrook, J. L., Cell surface receptors for protein toxins, in Botulinum Neurotoxin and Tetanus Toxin, Simpson, L. L., Ed., Academic Press, New York, 1989, 95-119.
11. Beers, W. H. and Reich, E., Isolation and characterization of Clostridium botulinum type B toxin, J. Biol. Chem., 244, 4473-4479, 1969.
12. Ohishi, I. and Sakaguchi, G., Molecular construction of Clostridium botulinum type F progenitor toxin, Appl. Microbiol., 29, 444-447, 1975.
13. Das Gupta, B. R. and Sugiyama, H., A common subunit structure in Clostridium botulinum type A, B and E toxins, Biochem. Biophys. Res. Commun., 48, 108-112, 1972.
14. Simpson, L. L., Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction, J. Pharmacol. Exp. Ther., 212, 16-21, 1980.
15. Sugui, S. and Sakaguchi, G., Molecular construction of Clostridium botulinum type A toxins, Infec. Immun., 12, 1262-1270, 1975.
16. Yang, K. H. and Sugiyama, H., Purification and properties of Clostridium botulinum type F toxin, Appl. Microbiol., 29, 598-603, 1975.
17. Miyazaki, S., Iwasaki, M., and Sakaguchi, G., Clostridium botulinum type D toxin: purification, molecular structure and some immunological properties, Infect. Immun., 17, 395-401, 1977.
18. Syuto, B. and Kubo, S., Structure and toxicity of Clostridium botulinum type C toxin, Japan. J. Med. Sci. Biol., 32132-32133, 1979.
19. Iwasaki, M., Ohishi, I., and Sakaguchi, G., Evidence that botulinum C2 toxin has two dissimilar components, Infect. Immun., 29, 390-394, 1980.
20. Ohishi, I., Iwasaka, M., and Sakaguchi, G., Purification and characterization of two components of botulinum C2 toxin, Infect. Immun., 30, 668-673, 1980.
21. Kozaki, S., Togashi, S., and Sakaguchi, G., Separation of Clostridium botulinum type A derivative toxin into two fragments, Japan. J. Med. Sci. Biol., 34, 61-68, 1981.
22. Simpson, L. L., A comparison of the pharmacological properties of Clostridium botulinum type C and type C2, J. Pharmacol. Exp. Ther., 223, 695-701, 1982.
23. Fujita, R., Fujinaga, Y., Inoue, K., Nakajima, H., Kumon, H., and Oguma, K., Molecular characterization of two forms of nontoxic-nonhemagglutinin components of Clostridium botulinum type A progenitor toxins, FEBS Lett., 376, 41-44, 1995.
24. Inoue, K., Fujinaga, Y., Watanabe, T., Ohyama, T., Takeshi K., Moriishi, K., Nakajima, H., Inoue, K., and Oguma, K., Molecular composition of Clostridium botulinum type A progenitor toxins, Infect. Immun., 64, 1589-1594, 1996.
25. Yang, G. H., Rhee, S. D., Jung, H. H., and Yang K. H., Organization and nucleotide sequence of genes for hemagglutinin components of Clostridium botulinum type B progenitor toxin, Biochem. Mol. Biol. Int., 39, 1141-1146, 1996.
26. Rodriguez, J. M., Collins, M. D., and East, A. K., Gene organization and sequence determination of the two botulinum neurotoxin gene clusters in Clostridium botulinum type A(B) strain NCTC 2916, Curr. Microbiol., 36, 226-231, 1998.
27. Henderson, I., Whelan, S. M., Davis, T. O., and Minton, N. P., Genetic characterization of the botulinum toxin complex of Clostridium botulinum strain NCTC 2916, FEMS Microbiol. Lett., 140, 151-158, 1996.
28. Ohyama, T., Watanabe, T., Fujinaga, Y., Inoue, K., Sunagawa, H., Fujii, N., Inoue, K., and Oguma, K., Characterization of nontoxic-nonhemagglutinin component of the two types of progenitor toxin (M and L) produced by Clostridium botulinum type D CB-16, Microbiol. Immunol., 39, 457-465, 1995.
29. Kubota, T., Yonekura, N., Hariya, Y., Isogai, E., Isogai, H., Amano, K., and Fujii, N., Gene arrangement in the upstream region of Clostridium botulinum type E and Clostridium butyricum BL6340 progenitor toxin genes is different from that of other types, FEMS Microbiol. Lett., 158, 215-221, 1998.
30. Bhandari, M., Campbell, K. D., Collins, M. D., and East A. K., Molecular characterization of the clusters of genes encoding the botulinum neurotoxin complex in Clostridium botulinum (Clostridium argentinense) type G and nonproteolytic Clostridium botulinum type B, Current Microbiol., 35, 207-214, 1997.
31. Hutson, R. A., Zhou, Y., Collins, M. D., Johnson, E. A., Hatheway, C. L., and Sugiyama, H., Genetic characterization of Clostridium botulinum type A containing silent type B neurotoxin gene sequences, J. Biol. Chem., 271, 10786-10792, 1996.
32. Ahnert-Hilger, G. and Bigalke, H., Molecular aspects of tetanus and botulinum neurotoxin poisoning, Prog. Neurobiol., 46, 83-96, 1995.
33. Singh, B. R., Li, B., and Read, D., Botulinum versus tetanus neurotoxins: why is botulinum neurotoxin but not tetanus neurotoxin a food poison? Toxicon, 33, 1541-1547, 1995.
34. Binz, T., Kurazono, H., Micaela, W., Frevert, J., Wernars, K., and Niemann, H., The complete sequence of botulinum neurotoxin Type A and comparison with other clostridial neurotoxins, J. Biol. Chem., 265, 9153-9158, 1990.
35. Willems, A., East, A. K., Lawson, P. A., and Collins, M. D., Sequence of the gene coding for the neurotoxin of Clostridium botulinum type A associated with infant botulism: comparison with other clostridial neurotoxins, Res. Microbiol., 144, 547-556, 1993.
36. Jung, H. H., Rhee, S. D., and Yang, K. H., Cloning of a Clostridium botulinum type B toxin gene fragment encoding the N-terminus of the heavy chain, FEMS Microbiol. Lett., 70, 69-72, 1992.
37. Hutson, R. A., Collins, M. D., East, A. K., and Thompson, D. E., Nucleotide sequence of the gene coding for nonproteolytic Clostridium botulinum type B neurotoxin: comparison with other clostridial neurotoxins, Curr. Microbiol., 28, 101-110, 1994.
38. Hauser, D., Eklund, M. W., Kurazono, H., Binz, T., Niermann, H., Gill, D. M., Goquet, P., and Popoff, M. R., Nucleotide sequence of Clostridium botulinum C1 neurotoxin, Nucl. Acids Res., 18, 4924-4924, 1990.
39. Hauser, D., Gibert, M., Marvaud, J. C., Eklund, M. W., and Popoff, M. R., Botulinal neurotoxin C1 complex genes, clostridial neurotoxin homology and genetic transfer in Clostridium botulinum, Toxicon, 33, 515-26, 1995.
40. Binz, T., Kurazona, H., Popoff, M., Eklund, M. W., Sakaguchi, G., Kozaki, S., Krieglstein, K., Henschen, A., Gill, D. M., and Niemann, H., Nucleotide sequence of the gene encoding Clostridium botulinum neurotoxin type D, Nucl. Acids Res., 18, 5556-5556, 1990.
41. Sunagawa, H., Ohyama, T., Watanabe, T., and Inoue, K., The complete amino acid sequence of the Clostridium botulinum type D neurotoxin, deduced by nucleotide sequence analysis of the encoding phage d-16 phi genome, J. Vet. Med. Sci., 54, 905-913, 1992.
42. Poulet, S., Hauser, D., Quanz, M., Niemann, H., and Popoff, M. R., Sequences of the botulinal neurotoxin E derived from Clostridium botulinum type E (strain Beluga) and Clostridium butyricum (strains ATCC 43181 and ATCC 43755), Biochem. Biophys. Res. Commun., 183, 107-113, 1992.
43. Whelan, S. M., Elmore, M. J., Bodsworth, N. J., Atkinson, T., and Minton, N. P., The complete amino acid sequence of the Clostridium botulinum type-E neurotoxin derived by nucleotide-sequence analysis of the encoding gene, Eur. J. Biochem., 204, 657-667, 1992.
44. East, A. K., Richardson, P. T., Allaway, D., Collins, M. D., Roberts, T. A., and Thompson, D. E., Sequence of the gene encoding type F neurotoxin of Clostridium botulinum, FEMS Microbiol. Lett., 75, 225-230, 1992.
45. Campbell, K., Collins, M. D., and East, A. K., Nucleotide sequence of the gene coding for Clostridium botulinum (Clostridium argentinense) type G neurotoxin: genealogical comparison with other clostridial neurotoxins, Biochim. Biophys. Acta, 1216, 487-491, 1993.
46. Campbell, K. D., Collins, M. D., and East, A. K., Gene probes for identification of the botulinal neurotoxin gene and specific identification of neurotoxin types B, E, and F. Also, B3: C. botulinum (strain nonproteolytic Eklund 2B) gene for neurotoxin type B. Accession # X70819. (Ref. same as B2); B4: C. botulinum (strain proteolytic B) gene for neurotoxin type B. Accession # X70817. (Ref. same as B2); B5: Clostridium botulinum neurotoxin type B (botB) gene, complete cds. Accession # M81186, J. Clin. Microbiol., 31, 2255-2262, 1993.
47. Krieglstein, K. G., DasGupta, B. R., and Henschen, A. H., Covalent structure of botulinum neurotoxin type A: location of sulfhydryl groups, and disulfide bridges, and identification of C-termini of light and heavy chains, J. Prot. Chem., 13, 49-57, 1994.
48. Eisel, U., Jarausch, W., Goretzki, K., Henschen, A., Engels, J., Weller, U., Hudel, M., Habermann, E., and Niemann, H., Tetanus toxin: primary structure, expression in E. coli, and homology with botulinum toxins, EMBO J., 5, 2495-2502, 1986.
49. Niemann, H., Molecular biology of clostridial neurotoxins, in Sourcebook of Protein Toxins, Alouf, J. E. and Freer, J. H., Eds., Academic Press, New York, 1991, 3203-384.
50. Johnson, E. A., Lin, W. J., Zhou, Y. T., and Bradshaw, M., Characterization of neurotoxin mutants in Clostridium botulinum type A, Clin. Infect. Diseases, 25, 2(Suppl.), 5168-5170, 1997.
51. Moriishi, K., Koura, M., Fujii, N., Fujinaga, Y., Inoue, K., Syuto, B., and Oguma K., Molecular cloning of the gene encoding the mosaic neurotoxin, composed of parts of botulinum neurotoxin types C1 and D, and PCR detection of this gene from Clostridium botulinum type C organisms, Appl. Environ. Microbiol., 62, 662-667, 1996.
52. Moriishi, K., Koura, M., Abe, N., Fujii, N., Fujinaga, Y., Inoue, K., and Ogumad K., Mosaic structures of neurotoxins produced from Clostridium botulinum types C and D organisms, Biochim. Biophys. Acta, 1307, 123-126, 1996.
53. Fujii, N., Kubota, T., Shirakawa, S., Kimura, K., Ohishi, I., Moriishi, K., Isogai, E., and Isogai, H., Characterization of component-I gene of botulinum C2 toxin and PCR detection of its gene in clostridial species, Biochem. Biophys. Res. Commun., 220, 353-359, 1996.
54. Lebeda, F. J. and Olson, M. A., Structural predictions of the channel-forming region of botulinum neurotoxin heavy chain, Toxicon, 33, 559-567, 1995.
55. Oblatt-Montal, M., Yamazaki, M., Nelson, R., and Montal, M., Formation of ion channels in lipid bilayers by a peptide with the predicted transmembrane sequence of botulinum neurotoxin A, Protein Sci., 4, 1490-1497, 1995.
56. Stevens, R. C., Evenson, M. L., Tepp, W., and Das Gupta, B. R., Crystallization and preliminary X-ray analysis of botulinum neurotoxin type A, J. Mol. Biol., 222, 877-880, 1991.
57. Lacy, D. B. and Stevens, R. C., Recombinant expression and purification of the botulinum neurotoxin type A translocation domain, Protein Expression Purification, 11, 195-200, 1997.
58. Burkard, F., Chen, F., Kuziemko, G. M., and Stevens R. C., Electron density projection map of the botulinum neurotoxin 900-kilodalton complex by electron crystallography, J. Struct. Biol., 120, 78-84, 1997.
59. Dickson, E. C. and Shevky, R., Botulism studies on the manner in which the toxin of Clostridium botulinum acts upon the body. II. The effect on the voluntary nervous system, J. Exp. Med., 37, 327-346, 1923.
60. Dickson, E. C. and Shevky, R., Botulism studies on the manner in which the toxin of Clostndium botulinum acts upon the body. I. The effect upon the autonomic nervous system, J. Exp. Med., 37, 711-731, 1923.
61. Burgen, A. S. V., Dickens, F., and Zatman, L. J., The action of botulinum toxin on the neuromuscular junction, J. Physiol. (London), 109, 10-24, 1949.
62. Wright, G. P., The neurotoxins of Clostridium botulinum and Clostridium tetani, Pharmacol. Rev., 7, 413-465, 1955.
63. Simpson, L. L., The origin, structure and pharmacological activity of botulinum toxin, Pharmacol. Rev., 33, 155-188, 1981.
64. Gundersen, C. B., The effects of botulinum toxin on the synthesis, storage, and release of acetylcholine, Prog. Neurobiol., 14, 99-119, 1980.
65. Wendon, L. M. B. and Gill, D. M., Tetanus toxin action on cultured nerve cells. Does it modify a neurotonal protein? Brain Res., 238, 292-297, 1982.
66. Wellhoner, H.-H., Tetanus neurotoxin, Rev. Physiol. Biochem. Pharmacol., 93, 1-68, 1982.
67. Simpson, L. L., Peripheral actions of the botulinum toxins, in Botulinum Neurotoxin and Tetanus Toxin, Simpson, L. L., Ed., Academic Press, New York, 1989, 153-178.
68. Middlebrook, J. L. and Dorland, R. B., Response of cultured mammalian cells to the exotoxins of Pseudomonas aeruginosa and Corynebacterium diphtheria. Differential cytotoxicity, Can. J. Microbiol., 23, 183-189, 1977.
69. Middlebrook, J. L. and Dorland, R. B., Protection of mammalian cells from diphtheria toxin by exogenous nucleotides, Can. J. Microbiol., 25, 285-290, 1979.
70. Middlebrook, J. L., Dorland, R. B., and Leppla, S. H., Association of diphtheria toxin with Vero cells: Demonstration of a receptor, J. Biol Chem., 253, 7325-7330, 1978.
71. Middlebrook, J. L., Dorland, R. B., and Leppla, S. H., Effects of lectins on the interaction of diphtheria toxin with mammalian cells, Exp. Cell Res., 121, 95-101, 1979.
72. Middlebrook, J. L., Effect of energy inhibitors on cell surface diphtheria toxin receptor numbers, J. Biol. Chem., 256, 7898-7904, 1981.
73. Simpson, L. L. and Rapport, M. M., The binding of botulinum toxin to membrane lipids, sphingolipids, steroids and fatty acids, J. Neurochem., 18, 1751-1759, 1971.
74. Kitamura, M., Iwamori, M., and Nagai, Y., Interaction between Clostridium botulinum neurotoxin and gangliosides, Biochim. Biophys. Acta, 628, 328-335, 1980.
75. Kozaki, S., Sakaguchi, G., Nishimura, M., Iwamori, M., and Nagai, Y., Inhibitory effect of ganglioside GT1B on the activities of Clostridium botulinum toxins, FEMS Microbiol. Lett., 21, 219-223, 1984.
76. Ochanda, J. O., Syuto, B., Ohishi, I., Naiki, M., and Kubo, S., Binding of Clostridium botulinum neurotoxin to gangliosides, J. Biochem., 100, 27-33, 1986.
77. Kozaki, S., Ogasawara, J., Shimote, Y., Kamata, Y., and Sakaguchi, G., Antigenic structure of Clostridium botulinum type B neurotoxin and its interaction with gangliosides, cerebrosides, and free fatty acids, Infect. Immun., 55, 3051-3056, 1987.
78. Kitamura, M., Binding of botulinum neurotoxin to the synaptosome fraction of rat brain, Naunyn-Schmiedeberg's Arch. Pharmacol., 295, 171-175, 1976.
79. Kozaki, S., Different neurotoxin serotypes do not share a common receptor, Naunyn-Schmiedeberg's Arch. Pharmacol., 308, 67-70, 1979.
80. Agui, T., Syuto, B., Oguma, K., Iida, H., and Kubo, S., Binding of Clostridium botulinum type C neurotoxin to rat brain synaptosomes, J. Biochem., 94, 521-527, 1983.
81. Nishiki, T., Kamata, Y., Nemoto, Y., Omori, A., Ito, T., Takahashi, M., and Kozaki, S., Identification of protein receptor for Clostridium botulinum type B neurotoxin in rat brain synaptosomes, J. Biol. Chem., 269, 10498-503, 1994.
82. Kozaki, S. and Sakaguchi, G., Binding to mouse brain synaptosomes of Clostridium botulinum type E derivative toxin before and after tryptic activation, Toxicon, 20, 841-846, 1982.
83. Morel, N., Israel, M., Manaranche, R., and Mastour-Franchon, P., Isolation of pure cholinergic nerve endings from Torpedo electric organ. Evaluation of their metabolic properties, J. Cell Biol., 75, 43-55, 1977.
84. Hirokawa, N. and Kitamura, M., Binding of Clostridium botulinum neurotoxin to the presynaptic membrane in the central nervous system, J. Cell Biol., 81, 43-49, 1979.
85. 125I-labeled botulinum neurotoxin at murine neuromuscular junction and its binding to rat brain synaptosomes, Toxicon, 20, 141-148, 1982.
86. 125I-labeled botulinum neurotoxins with nerve terminals. II. Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis, J. Cell Biol., 103, 535-544, 1986.
87. Kozaki, S., Akira, M., Yoichi, K., Jun, O., and Genji, S., Immunological characterization of papain-induced fragments of Clostridium botulinum type A neurotoxin and interaction of the fragments with brain synaptosomes, Infect. Immun., 57, 2634-2639, 1989.
88. Schengrund, C. L., DasGupta, B. R., Hughes, C. A., and Ringler, N. J., Ganglioside-induced adherence of botulinum and tetanus neurotoxins to adducin, J. Neurochem., 66, 2556-2561, 1996.
89. Kamata, Y., Yoshimoto, M., and Kozaki, S., Interaction between botulinum neurotoxin type A and ganglioside: ganglioside inactivates the neurotoxin and quenches its tryptophan fluorescence, Toxicon, 35, 1337-1340, 1997.
90. Juzans, P., Molgo, J., Faille, L., and Angaut-Petit, D., Synaptotagmin II immunoreactivity in normal and botulinum type-A treated mouse motor nerve terminals, Pflugers Archiv-Eur. J. Physiol., 431(Suppl 2), R283-284, 1996.
91. Nishiki, T., Tokuyama, Y., Kamata, Y., Nemoto, Y., Yoshida, A., Sato, K., Sekiguchi, M., Takahashi M., and Kozaki, S., The high-affinity binding of Clostridium botulinum type B neurotoxin to synaptotagmin II associated with gangliosides GT1b/ GD1a, FEBS Lett., 378, 253-257, 1996.
92. Nishiki, T., Tokuyama, Y., Kamata, Y., Nemoto, Y., Yoshida, A., Sekiguchi M., Takahashi M., and Kozaki, S., Binding of botulinum type B neurotoxin to Chinese hamster ovary cells transfected with rat synaptotagmin II cDNA, Neurosci. Lett., 208, 105-8, 1996.
93. Simpson, L. L., Molecular pharmacology of botulinum toxin and tetanous toxin, Ann. Rev. Pharmacol. Toxicol., 26, 427-453, 1986.
94. Bandyopadhyay, S., Clark, A. W., Das Gupta, B., and Sathyamoorthy, V., Role of the heavy and light chains of botulinum neurotoxin in neuromuscular paralysis, J. Biol. Chem., 262, 2660-2663, 1987.
95. Kozaki, S., Sakaguchi, S., and Sakaguchi, G., Mild trypsin action of type E toxicity increased 90-fold, Infect. Immun., 10, 750-756, 1974.
96. Shone, C. C., Hambleton, P., and Melling, J., Inactivation of Clostridium botulinum type A neurotoxin by trypsin and purification of two tryptic fragments. Proteolytic action near the COOH-terminus of the heavy subunit destroys toxin-binding activity, Eur. J. Biochem., 15, 75-82, 1985.
97. Schiavo, G., Shone, C. C., Bennett, M. K., Scheller, R. H., and Montecucco, C., Botulinum neurotoxin type C cleaves a single Lys-Ala bond within the carboxyl-terminal region of syntaxins, J. Biol. Chem., 270, 10566-10570, 1995.
98. Tonello, F., Morante, S., Rossetto, O., Schiavo, G., and Montecucco, C., Tetanus and botulism neurotoxins: a novel group of zinc-endopeptidases, Adv. Exp. Med. Biol., 389, 251-260, 1996.
99. Montecucco, C., Schiavo, G., and Rossetto, O., The mechanism of action of tetanus and botulinum neurotoxins, Arch. Toxicol., Supplement, 18, 342-354, 1996.
100. Linial M., Bacterial neurotoxins-a thousand years later, Israel J. Med. Sci., 31, 591-595, 1995.
101. Ahnert-Hilger, G. and Bigalke H., Molecular aspects of tetanus and botulinum neurotoxin poisoning, Prog. Neurobiol., 46, 83-96, 1995.
102. Oguma, K., Fujinaga, Y., and Inoue, K., Structure and function of Clostridium botulinum toxins, Microbiol. Immunol., 39, 161-168, 1995.
103. Fu, F. N., Lomneth, R. B., Cai, S., and Singh, B. R., Role of zinc in the structure and toxic activity of botulinum neurotoxin, Biochemistry, 37, 5267-5278, 1998.
104. Hohne-Zell, B. and Gratzl, M., Adrenal chromaffin cells contain functionally different SNAP-25 monomers and SNAP-25/syntaxin heterodimers, FEBS Lett., 394, 109-116, 1996.
105. 2+-induced insulin exocytosis, EMBO J., 15, 6951-6959, 1996.
106. Cheatham, B., Volchuk, A., Kahn, C. R., Wang, L., Rhodes, C. J., and Klip, A., Insulin-stimulated translocation of GLUT4 glucose transporters requires SNARE-complex proteins, Proc. Natl. Acad. Sci. U.S.A., 93, 15169-15173, 1996.
107. Chen, F., Foran, P., Shone, C. C., Foster, K. A., Melling, J., and Dolly, J. O., Botulinum neurotoxin B inhibits insulin-stimulated glucose uptake into 3T3L1 adipocytes and cleaves cellubrevin unlike BoNT A which failed to proteolyze the SNAP-23 present, Biochemistry, 36, 5719-5728, 1997.
108. Macaulay, S. L., Hewish, D. R., Gough, K. H., Stoichevska, V., MacPherson, S. F., Jagadish, M., and Ward, C. W., Functional studies in 3T3L1 cells support a role for SNARE proteins in insulin stimulation of GLUT4 translocation, Biochem. J., 324, 217-224, 1997.
109. Walch-Solimena, C., Blasi, J., Edelmann, L., Chapman, E. R., von Mollard, G. F., and Jahn, R., The t-SNAREs syntaxin 1 and SNAP-25 are present on organelles that participate in synaptic vesicle recycling, J. Cell. Biol., 128, 637-645, 1995.
110. Pellizzari, R., Rossetto, O., Lozzi, L., Giovedi, S., Johnson, E., Shone, C. C., and Montecucco, C., Structural determinants of the specificity for synaptic vesicle-associated membrane protein/synaptobrevin of tetanus and botulinum type B and G neurotoxins, J. Biol. Chem., 271, 20353-20358, 1996.
111. Pellizzari, R., Mason, S., Shone, C. C., and Montecucco, C., The interaction of synaptic vesicle-associated membrane protein/synaptobrevin with botulinum neurotoxins D and F, FEBS Lett., 409, 339-342, 1997.
112. Schmidt, J. J. and Bostian, K. A., Proteolysis of synthetic peptides by type A botulinum neurotoxin, J. Prot. Chem., 14, 703-708, 1995.
113. Otto, H., Hanson, P. I., Chapman, E. R., Blasi, J., and Jahn, R., Poisoning by botulinum neurotoxin A does not inhibit formation or disassembly of the synaptosomal fusion complex, Biochem. Biophys. Res. Commun., 212, 945-952, 1995.
114. 2+-dependent exocytosis, J. Biol. Chem., 271, 20227-20230, 1996.
115. Foran, P., Lawrence, G. W., Shone, C. C., Foster, K. A., and Dolly, J. O., Botulinum neurotoxin C1 cleaves both syntaxin and SNAP-25 in intact and permeabilized chromaffin cells: correlation with its blockade of catecholamine release, Biochemistry, 35, 2630-2636, 1996.
116. Wictome, M., Rossetto, O., Montecucco, C., and Shone, C. C., Substrate residues N-terminal to the cleavage site of botulinum type B neurotoxin play a role in determining the specificity of its endopeptidase activity, FEBS Lett., 386, 133-136, 1996.
117. Rhee, S. D., Jung, H. H., Yang, G. H., Moon, Y. S., and Yang, K. H., Cleavage of the synaptobrevin/ vesicle-associated membrane protein (VAMP) of the mouse brain by the recombinant light chain of Clostridium botulinum type B toxin, FEMS Microbiol. Lett., 150, 203-208, 1997.
118. Foran, P., Lawrence, G., and Dolly, J. O., Blockade by botulinum neurotoxin B of catecholamine release from adrenochromaffin cells correlates with its cleavage of synaptobrevin and a homologue present on the granules, Biochemistry, 34, 5494-5503, 1995.
119. Stanley, E. F. and Mirotznik, R. R., Cleavage of syntaxin prevents G-protein regulation of presynaptic calcium channels, Nature, 385, 340-343, 1997.
120. Schiavo, G., Stenbeck, G., Rothman, J. E., and Sollner, T. H., Binding of the synaptic vesicle v-SNARE, synaptotagmin, to the plasma membrane t-SNARE, SNAP-25, can explain docked vesicles at neurotoxin-treated synapses, Proc. Natl. Acad. Sci. U.S.A., 94, 769-772; 997-1001, 1997.
121. 2+ partially rescues synaptic transmission in hippocampal cultures treated with botulinum toxin A and C, but not tetanus toxin, J. Neurosci., 17, 7190-7202, 1997.
122. Ekong, T. A., Feavers, I. M., and Sesardic, D., Recombinant SNAP-25 is an effective substrate for Clostridium botulinum type A toxin endopeptidase activity in vitro, Microbiology, 143, 3337-347, 1997.
123. Marsal, J., Ruiz-Montasell, B., Blasi, J., Moreira, J. E., Contreras, D., Sugimori, M., and Llinas, R., Block of transmitter release by botulinum C1 action on syntaxin at the squid giant synapse, Proc. Natl. Acad. Sci. U.S.A., 94, 14871-14876, 1997.
124. O'Connor, V., Heuss, C., De Bello, W. M., Dresbach, T., Charlton, M. P., Hunt, J. H., Pellegrini, L. L., Hodel, A., Burger, M. M., Betz, H., Augustine, G. J., and Schafer, T., Disruption of syntaxin-mediated protein interactions blocks neurotransmitter secretion, Proc. Natl. Acad. Sci. U.S.A., 94, 12186-12191, 1997.
125. Glenn, D. E. and Burgoyne, R. D., Botulinum neurotoxin light chains inhibit both Ca(2+)-induced and GTP analogue-induced catecholamine release from permeabilised adrenal chromaffin cells, FEBS Lett., 386, 137-140, 1996.
126. Lawrence, G. W., Foran, P., Mohammed, N., DasGupta, B. R., and Dolly, J. O., Importance of two adjacent C-terminal sequences of SNAP-25 in exocytosis from intact and permeabilized chromaffin cells revealed by inhibition with botulinum neurotoxins A and E, Biochemistry, 36, 3061-3067, 1997.
127. Gutierrez, L. M., Viniegra, S., Rueda, J., Ferrer-Montiel, A. V., Canaves, J. M., and Montal, M., A peptide that mimics the C-terminal sequence of SNAP-25 inhibits secretory vesicle docking in chromaffin cells, J. Biol. Chem., 211, 2634-2639, 1997.
128. Shimazaki, Y., Nishiki, T., Omori, A., Sekiguchi, M., Kamata, Y., Kozaki, S., and Takahashi, M., Phosphorylation of 25-kDa synaptosome-associated protein. Possible involvement in protein kinase C-mediated regulation of neurotransmitter release, J. Biol. Chem., 271, 14548-14553, 1996.
129. Thesleff, S. and Lundh, H., Mode of action of Botulinum toxin and the effect of drug antagonist, Adv. Cytopharmacol., 3, 35-43, 1979.
130. Thesleff, S., Pharmacologic antagonism of clostridial toxins, in Botulinum Neurotoxin and Tetanus Toxin, Simpson, L.L., Ed., Academic Press, New York, 1989, 281-298.
131. Ashton, A. C. and Dolly, J. O., Microtubule-dissociating drugs and A23187 reveal differences in the inhibition of synaptosomal transmitter release by botulinum neurotoxins types A and B, J. Neurochem., 56, 827-835, 1991.
132. Adler, M., Scovill, J., Parker, G., Lebeda, F. J., Piotrowski, J., and Deshpande, S. S., Antagonism of botulinum toxin-induced muscle weakness by 3,4-diaminopyridine in rat phrenic nerve-hemidiaphragm preparations, Toxicon, 33, 527-537, 1995.
133. Adler, M., Macdonald, D. A., Sellin, L. C., and Parker, G. W., Effect of 3,4-diaminopyridine on rat extensor digitorum longus muscle paralyzed by local injection of botulinum neurotoxin, Toxicon, 34, 237-249, 1996.
134. Leppla, S., Dorland, R. B., and Middlebrook, J. L., Inhibition of diphtheria toxin degradation and cytotoxic action by chloroquine, J. Biol. Chem., 255, 2247-2250, 1980.
135. Dorland, R. B., Middlebrook, J. L., and Leppla, S. H., Effect of ammonium chloride on receptor-mediated uptake of diphtheria toxin by vero cells, Exp. Cell Res., 134, 319-327, 1981.
136. Fitzgerald, D., Morris, R. E., and Saelinger, C. B., Receptor mediated internalization of pseudomonas toxin by mouse fibroblasts, Cell, 21, 867-873, 1980.
137. Deshpande, S. S., Sheridan, R. E., and Adler, M., Efficacy of certain quinolines as pharmacological antagonists in botulinum neurotoxin poisoning, Toxicon, 1997 35, 433-445, 1980.
138. Sheridan, R. E., Deshpande, S. S., Nicholson, J. D., and Adler, M., Structural features of aminoquinolines necessary for antagonist activity against botulinum neurotoxin, Toxicon, 35, 1439-1451, 1997.
139. Bakry, N., Yoichi, K., and Simpson, L., Lectins from triticum vulgaris and limax flavus are universal antagonists of botulinum neurotoxin and tetanus toxin, J. Phamacol. Exp. Therap., 258, 830-836, 1991.
140. Deshpande, S. S., Sheridan, R. E., and Adler, M., A study of zinc-dependent metalloendopeptidase inhibitors as pharmacological antagonists in botulinum neurotoxin poisoning, Toxicon, 33, 551-557, 1995.
141. Adler, M., Dinterman, R. E., and Wannemacher, R. W., Protection by the heavy metal chelator N,N,N′,N′-tetrakis(2-pyridylmethyl)ethylenediamine (TPEN) against the lethal action of botulinum neurotoxin A and B, Toxicon, 35, 1089-1100, 1997.
142. Cardoso, F. and Jankovic, J., Clinical use of botulinum neurotoxins, Curr. Topics Microbiol. Immunol., 195, 123-141, 1995.
143. Borodic, G., Johnson, E., Goodnough, M., and Schantz, E., Botulinum toxin therapy, immunologic resistance, and problems with available materials, Neurology, 46, 26-29, 1996.
144. Erbguth, F. J., Historical note on the therapeutic use of botulinum toxin in neurological disorders, J. Neurol., Neurosurg. Psych., 60, 151, 1996.
145. Lagueny, A. and Burbaud, P., Mechanism of action, clinical indication, and results of treatment of botulinum toxin, Neurophysiologie Clinique, 26, 216-226, 1996.
146. Montecucco, C., Schiavo, G., Tugnoli, V., and de Grandis, D., Botulinum neurotoxins: mechanism of action and therapeutic applications, Mol. Med. Today, 2, 418-424, 1996.
147. Tsui, J. K., Botulinum toxin as a therapeutic agent, Pharmacol. Therapeutics, 72, 13-24, 1996.
148. Schantz, E. J. and Johnson, E. A., Botulinum toxin: the story of its development for the treatment of human disease, Perspectives Biol. Med., 40, 317-327, 1997.
149. Wheeler, A. H., Therapeutic uses of botulinum toxin, Am. Family Physician, 55, 541-545, 548, 1997.
150. Kessler, K. R. and Benecke, R., Botulinum toxin: from poison to remedy, Neurotoxicology, 18, 761-770, 1997.
151. Pearce, L. B., First, E. R., MacCallum, R. D., and Gupta, A., Pharmacologic characterization of botulinum toxin for basic science and medicine, Toxicon, 35, 1373-1412, 1997.
152. Berardelli, A., Abbruzzese, G., Bertolasi, L., Cantarella, G., Carella, F., Curra, A., De Grandis, D., DeFazio, G., Galardi, G., Girlanda, P., Livrea, P., Modugno, N., Priori, A., Ruoppolo, G. L., Vacca, L., and Manfredi, M., Guidelines for the therapeutic use of botulinum toxin in movement disorders. Italian Study Group for Movement Disorders, Italian Society of Neurology, Italian J. Neurological Sciences, 18, 261-269, 1997.
153. Cuevas, C., Madrazo, I., Magallon, E., Zamorano, C., Neri, G., and Reyes, E., Botulinum toxin-A for the treatment of hemifacial spasm, Arch. Medical Res., 26, 405-408, 1995.
154. Sloop, R. R., Cole, B. A., and Escutin, R. O., Human response to botulinum toxin injection: Type B compared with type A, Neurology, 49, 189-194, 1997.
155. Eleopra, R., Tugnoli, V., Rossetto, O., Montecucco, C., and De Grandis, D., Botulinum neurotoxin serotype C: a novel effective botulinum toxin therapy in human, Neurosci. Lett, 224, 91-94, 1997.
156. Poewe, W., Deuschl, G., Nebe, A., Feifel, E., Wissel, J., Benecke, R., Kessler, K. R., Ceballos-Baumann, A. O., Ohly, A., Oertel, W., and Kunig, G., What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group, J. Neurol. Neurosurg. Psychiatry, 64, 13-17, 1998.
157. Zwirner, P., Murry, T., and Woodson, G. E., Effects of botulinum toxin on vocal tract steadiness in patients with spasmodic dysphonia, European Archives of Oto-Rhino-Laryngology, 254, 391-395, 1997.
158. Albanese, A., Bentivoglio, A. R., Cassetta, E., Viggiano, A., Maria, G., and Gui, D., The use of botulinum toxin in the alimentary tract, Alimentary Pharmacol. Therapeutics, 9, 599-604, 1995.
159. Bhutani, M. S., Gastrointestinal uses of botulinum toxin, Am. J. Gastroenterol., 92, 929-933, 1997.
160. Albanese, A., Maria, G., Bentivoglio, A. R., Brisinda, G., Cassetta, E., and Tonali, P., Severe constipation in Parkinson's disease relieved by botulinum toxin, Movement Disorders, 12, 764-766, 1997.
161. Mezaki, T., Kaji, R., Kohara, N., and Kimura, J., Development of general weakness in a patient with amyotrophic lateral sclerosis after focal botulinum toxin injection, Neurology, 46, 845-846, 1996.
162. Carruthers, A., Kiene, K., and Carruthers, J., Botulinum A exotoxin use in clinical dermatology, J. Am. Acad. Dermatol., 34, 788-797, 1996.
163. Ellis, D. A. and Tan, A. K., Cosmetic upper-facial rejuvenation with botulinum, J. Otolaryngol., 26, 92-96, 1997.
164. Carter, S. R. and Seiff, S. R., Cosmetic botulinum toxin injections, Int. Ophthalmol. Clin., 37, 69-79, 1997.
165. Carruthers, A. and Carruthers, J., Cosmetic uses of botulinum A exotoxin, Advances Dermatol., 12, 325-348, 1997.
166. Bikhazi, N. B. and Maas, C. S., Refinement in the rehabilitation of the paralyzed face using botulinum toxin, Otolaryngology-Head Neck Surg., 117, 303-307, 1997.
167. Ellis, D. A., Chi, P. L., and Tan, A. K., Facial rejuvenation with botulinum, Dermatol. Nursing, 9, 329-333, 365, 1997.
168. Spencer, R. F., Tucker, M. G., Choi, R. Y., and McNeer, K. W., Botulinum toxin management of childhood intermittent exotropia, Ophthalmology, 104, 1762-1767, 1997.
169. Diels, H. J. and Combs, D., Neuromuscular retraining for facial paralysis, Otolaryngologic Clinics N. Am., 30, 727-743, 1997.
170. Marchand, L., Treatment of essential tremor, Union Medicale du Canada, 124, 32-34, 1995.
171. Henderson, J. M., Ghika, J. A., Van Melle, G., Haller, E., and Einstein, R., Botulinum toxin A in nondystonic tremors, Eur. Neurol., 36, 29-35, 1996.
172. Jankovic, J., Schwartz, K., Clemence, W., Aswad, A., and Mordaunt, J., A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor, Movement Disorders, 11, 250-256, 1996.
173. Brennan, H. G. and Koch, R. J., Management of aging neck, Facial Plastic Surg., 12, 241-255, 1996.
174. Sampaio, C., Ferreira, J. J., Pinto, A. A., Crespo, M., Ferro, J. M., and Castro-Caldas, A., Botulinum toxin type A for the treatment of arm and hand spasticity in stroke patients, Clin. Rehab., 11, 3-7, 1997.
175. Wissel, J., Masuhr, F., Schelosky, L., Ebersbach, G., and Poewe, W., Quantitative assessment of botulinum toxin treatment in 43 patients with head tremor, Movement Disorders, 12, 722-726, 1997.
176. Deymeer, F., Oge, A. E., Serdaroglu, P., Yazici, J., Ozdemir, C., and Baslo, A., The use of botulinum toxin in localizing neuromyotonia to the terminal branches of the peripheral nerve, Muscle Nerve, 21, 643-646, 1998.
177. Kerty, E. and Stien, R., Treatment of spasticity with botulinum toxin, Tidsskrift for Den Norske Laegeforening, 117, 2022-2024, 1997.
178. Hesse, S. and Mauritz, K. H., Management of spasticity, Curr. Opin. Neurol., 10, 498-501, 1997.
179. Ko, C. K. and Ward, A. B., Management of spasticity, Br. J. Hosp. Med., 58, 400-405, 1997.
180. Bentley, C., Botulinum neurotoxin A in ophthalmology, Ophthalmic Physiological Optics, 16(Suppl. 1), S9-S14, 1997.
181. Carruthers, J. D. and Carruthers, A., Botulinum A exotoxin in clinical ophthalmology, Can. J. Ophthalmol., 31, 389-400, 1996.
182. Kikkawa, D. O. and Kim, J. W., Lower-eyelid blepharoplasty, Int. Ophthalmol. Clin., 37, 163-178, 1997.
183. Huber, A., Use of botulinum toxin in ophthalmology, Klinische Monatsblatter fur Augenheilkunde, 210, 289-292, 1997.
184. Tapiero, B., Robert, P. Y., Adenis, J. P., and Riss, I., Use of botulinum toxin in ophthalmology: Current concepts and problems, J. Francais d' Ophtalmologie, 20, 134-145, 1997.
185. Acheson, J. F., Bentley, C. R., Shallo-Hoffmann, J., and Gresty, M. A., Dissociated effects of botulinum toxin chemodenervation on ocular deviation and saccade dynamics in chronic lateral rectus palsy, Br. J. Ophthalmol., 82, 67-71, 1998.
186. Papazian, O. and Alfonso, I., Cerebral palsy therapy, Revista de Neurologia, 25, 728-739, 1997.
187. Arens, L. J., Leary, P. M., and Goldschmidt, R. B., Experience with botulinum toxin in the treatment of cerebral palsy, S. Afr. Med. J., 87, 1001-1003, 1997.
188. Pascual-Pascual, S. I., Sanchez de Muniain, P., Roche, M. C., and Pascual-Castroviejo, I., Botulinum toxin as a treatment for infantile cerebral palsy, Revista de Neurologia, 25, 1369-1375, 1997.
189. Jost, W. H. and Schimrigk, K., Botulinum toxin in therapy of anal fissure, Lancet, 345, 188-189, 1995.
190. Goel, A. K. and Seenu, V., Botulinum toxin in the management of anal fissure: innovative use of a familiar agent, Tropical Gastroenterol., 16, 68-69, 1995.
191. Jost, W. H., One hundred cases of anal fissure treated with botulin toxin: early and long-term results, Diseases Colon Rectum, 40, 1029-1032, 1997.
192. Maria, G., Cassetta, E., Gui, D., Brisinda, G., Bentivoglio, A. R., and Albanese, A., A comparison of botulinum toxin and saline for the treatment of chronic anal fissure, N. Engl. J. Med., 338, 257-259. 338, 217-220, 1998.
193. Jost, W. H., Muller-Lobeck, H., and Merkle, W., Involuntary contractions of the striated anal sphincters as a cause of constipation: report of a case, Diseases Colon Rectum, 41, 258-260, 1998.
194. Steinhardt, G. F., Naseer, S., and Cruz, O. A., Botulinum toxin: novel treatment for dramatic urethral dilatation associated with dysfunctional voiding, J. Urol., 158, 190-191, 1997.
195. Werner, J. A. and Gottschlich, S., Recent advances. Otorhinolaryngology, Br. Med. J., 315, 354-357, 1997.
196. Laskawi, R., The use of botulinum toxin in Otorhinolaryngology - experiences and outlook (German), Laryngo-Rhino-Otologie, 76, 656-659, 1997.
197. Egan, M. F., Apud, J., and Wyatt, R. J., Treatment of tardive dyskinesia, Schizophrenia Bulletin, 23, 583-609, 1997.
198. Liguori, R., Cordivari, C., Lugaresi, E., and Montagna, P., Botulinum toxin A improves muscle spasms and rigidity in stiff-person syndrome, Movement Disorders, 12, 1060-1063, 1997.
199. Horgan, S. E., Lee, J. P., and Bunce, C., The long-term use of botulinum toxin for adult strabismus, J. Pediatric Ophthalmol. Strabismus, 35, 9-16, 1998.
200. Drobik, C. and Laskawi, R., Frey's syndrome: treatment with botulinum toxin, Acta Oto-Laryngologica, 115, 459-461, 1995.
201. Schulze-Bonhage, A., Schroder, M., and Ferbert, A., Botulinum toxin in the therapy of gustatory sweating, J. Neurol., 243, 143-146, 1996.
202. Bjerkhoel, A. and Trobbe, O., Frey's syndrome: treatment with botulinum toxin, J. Laryngol. Otol., 111, 839-844, 1997.
203. Laccourreye, O., Muscatelo, L., Naude, C., Bonan, B., and Brasnu, D., Botulinum toxin type A for Frey's syndrome: a preliminary prospective study, Annals Otol. Rhinol. Laryngol, 107, 52-55, 1998.
204. Laskawi, R., Drobik, C., and Schonebeck, C., Up-to-date report of botulinum toxin type A treatment in patients with gustatory sweating (Frey's syndrome), Laryngoscope, 108, 381-384, 1998.
205. Naumann, M., Hofmann, U., Bergmann, I., Hamm, H., Toyka, K. V., and Reiners, K., Focal hyperhidrosis: effective treatment with intracutaneous botulinum toxin, Arch. Dermatol., 134, 301-304, 1998.
206. Schiano, T. D., Parkman, H. P., Miller, L. S., Dabezies, M. A., Cohen, S., and Fisher, R. S., Use of botulinum toxin in the treatment of achalasia, Digest. Diseases, 16, 14-22, 1998.
207. Doellgast, G. J., Brown, J. E., Koufman, J. A., and Hatheway, C. L., Sensitive assay for measurement of Abs to Clostridium botulinum neurotoxins A, B, and E: use of hapten-labeled-Ab elution to isolate specific complexes, J. Clin. Microbiol., 35, 578-583, 1997.
208. Greene, P. E. and Fahn, S., Response to botulinum toxin F in seronegative botulinum toxin A-resistant patients, Movement Disorders, 11, 181-184, 1996.
209. Goschel, H., Wohlfarth, K., Frevert, J., Dengler, R., and Bigalke, H., Botulinum A toxin therapy: neutralizing and nonneutralizing Abs - therapeutic consequences, Exp. Neurol., 147, 96-102, 1997.
210. Akama, K., Ito, A., Yamamoto, A., and Sadahiro, S., Reversion of toxicity of tetanous toxoid, Jap. J. Med. Sci. Biol., 24, 181-182, 1971.
211. Akama, K., Kameyama, S., Otani, S., Sadahiro, S., and Murata, R., Reversion of toxicity of diphtheria toxoid, Jap. J. Med. Sci Biol., 24, 183-187, 1971.
212. Atassi, M. Z., Chemical modification and cleavage of proteins and chemical strategy in immunochemical studies of proteins, in Immunochemistry of Proteins, vol. 1, Atassi, M. Z., Ed., Plenum Press, New York, 1977, 1-161.
213. Kozaki, S., Miyazaki, S., and Sakaguchi, G., Development of anti-toxin with each of two complementary fragments of Clostridium botulinum type B derivative toxin, Infect. Immun., 18, 761-766, 1977.
214. Kozaki, S., Kamata, Y., Nagai, T., Ogasawara, J., and Sakaguchi, G., The use of monoclonal antibodies to analyze the structure of Clostridium botulinum type E derivative toxin, Infect. Immun., 52, 786-791, 1986.
215. Simpson, L. L., The study of clostridial and related toxins. The search for unique mechanisms and common denominators, J. Physiol. (Paris), 84, 143-151, 1990.
216. Tsuzuki, K., Yokosawa, N., Syuto, B., Ohishi, I., Fujii, N., Kimura, K., and Oguma, K., Establishment of a monoclonal antibody recognizing an antigenic site common to Clostridium botulinum type b, C1, D, and E toxins and tetanus toxin, Infect. Immun., 56, 898-902, 1988.
217. Chan, W. L., Sesardic, D., and Shone, C. C., Proliferative T cell response to botulinum toxin type A in mice, in Botulinum and Tetanus Neurotoxins: Neutotrnsmission and Biomedical Aspects, DasGupta, B. R., Ed, Plenum Press, New York, 1993, 337-339.
218. Cenci di Bello, I., Poulain, B., Shone, C. C., Tauc, L., and Dolly, J. O., Antagonism of the intracellular action of botulinum neurotoxin type A by monoclonal antibodies that map to light chain epitopes, Eur. J. Biochem., 219, 161-169, 1994.
219. Demotz, S., Matricardi, P. M., Irle, C., Panina, P., Lanzavecchia, A., and Corradin, G., Processing of tetanus toxin by human antigen-presenting cells. Evidence for donor and epitope-specific processing pathways, J. Immunol., 143, 3881-3886, 1989.
220. Demotz, S., Lanzavecchia, A., Eisel, U., Niemann, H., Widmann, C., and Corradin, G., Delineation of several DR-restricted tetanus toxin T cell epitopes, J. Immunol., 142, 394-402, 1989.
221. Ho, P. C., Mutch, D. A., Winkel, K. D., Saul, A. J., Jones, G. L., Doran, T. J., and Rzepczyk, C. M., Identification of two promiscuous T cell epitopes from tetanus toxin, Eur. J. Immunol., 20, 477-483, 1990.
222. Reece, J. C., Geysen, H. M., and Rodda, S. J., Mapping the major human T helper epitopes of tetanus toxin. The emerging picture, J. Immunol., 151, 6175-6184, 1993.
223. Fischer, P. M. and Howden, M. E. H., Synthetic peptide antigens of tetanus toxin, Mol. Immunol., 31, 1141-1148, 1994.
224. Makoff, A. J., Ballantine, S. P., Smallwood, A. E., and Fairweather, N. F., Expression of tetanus toxin fragment C in E. coli: its purification and potential use as a vaccine, Bio/Technology, 7, 1043-1046, 1989.
225. Clare, J. J., Rayment, F. B., Ballantine, S. P., Sreekrishna, K., and Romanos, M. A., High-level expression of tetanus toxin fragment C in Pichia pastoris strains containing multiple tandem integrations of the gene, Bio/Technology, 9, 455-460, 1991.
226. LaPenotiere, H. F., Clayton, M. A., and Middlebrook, J. L., Expression of a large, nontoxic fragment of botulinum neurotoxin serotype A and its use as an immunogen, Toxicon, 33, 1383-1386, 1995.
227. Clayton, M. A., Clayton, J. M., Brown, D. R., and Middlebrook, J. L., Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli, Infect. Immun., 63, 2738-2742, 1995.
228. Middlebrook, J. L., Protection strategies against botulinum toxin, Adv. Exp. Med. Biol., 383, 93-98, 1995.
229. Whalen, R. L., Dempsey, D. J., Thompson, L. M., Bucknell, K., Kunitomo, R., Okazaki, Y., and Harasaki, H., Microencapsulated vaccines to provide prolonged immunity with a single administration, ASAIO J., 42, M649-M654, 1996.
230. Dertzbaugh, M. T. and West, M. W., Mapping of protective and cross-reactive domains of the type A neurotoxin of Clostridium botulinum, Vaccine, 14, 1538-1544, 1996.
231. Amersdorfer, P., Wong, C., Chen, S., Smith., T., Deshpande, S., Sheridan, R., Finnern, R., and Marks, J. D., Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage Ab libraries, Infect. Immun., 65, 3743-3752, 1997.
232. Kubota, T., Watanabe, T., Yokosawa, N., Tsuzuki, K., Indoh, T., Moriishi, K., Sanda, K., Maki, Y., Inoue, K., and Fujii, N., Epitope regions in the heavy chain of Clostridium botulinum type E neurotoxin recognized by monoclonal antibodies, Appl. Environ. Microbiol., 63, 1214-1218, 1997.
233. Kiyatkin, N., Maksymowych, A. B., and Simpson, L. L., Induction of an immune response by oral administration of recombinant botulinum toxin, Infect. Immun., 65, 4586-4591, 1997.
234. Atassi, M. Z. and Smith, J. A., A proposal for the nomenclature of antigen sites in peptides and proteins, Immunochemistry, 15, 609-610, 1978.
235. Kazim, A. L. and Atassi, M. Z., A novel and comprehensive synthetic approach for the elucidation of protein antigenic structures: Determination of the full antigenic profile of the α-chain of human haemoglobin, Biochem. J., 191, 261-264, 1980.
236. Kazim, A. L. and Atassi, M. Z., Structurally inherent antigenic sites: localization of the antigenic sites of the α-chain of human haemoglobin in three host species by a comprehensive synthetic approach, Biochem. J., 203, 201-208, 1982.
237. Bixler, G. S. and Atassi, M. Z., Molecular localization of the full profile of the continuous regions recognized by myoglobin primed T cells using synthetic overlapping peptides encompassing the entire molecule, Immunol. Commun., 12, 593-603, 1983.
238. Bixler, G. S. and Atassi, M. Z., T-Cell recognition of myoglobin. Localization of the sites stimulating T-Cell proliferative responses by synthetic overlapping peptides encompassing the entire molecule, J. Immunogen., 11, 339-353, 1984.
239. Kazim, A. L. and Atassi, M. Z., Prediction and confirmation by synthesis of two antigenic sites in human haemoglobin by extrapolation from the known antigenic structure of sperm whale myoglobin, Biochem. J., 167, 275-278, 1977.
240. Kazim, A. L. and Atassi, M. Z., First consequences of the determination of the entire antigenic structure of sperm whale myoglobin, Adv. Exp. Med. Biol., 98, 19-40, 1978.
241. Yoshioka, N. and Atassi, M. Z., Antigenic structure of human haemoglobin: Localization of the antigenic sites of the β-chain in three host species by synthetic overlapping peptides representing the entire chain, Biochem. J., 234, 441-447, 1986.
242. Atassi, M. Z., Antigenic structures of proteins. Their determination has revealed important aspects of immune recognition and generated strategies for synthetic mimicking of protein binding sites, Eur. J. Biochem., 145, 1-20, 1984.
243. Dolimbek, B. Z. and Atassi, M. Z., α-bungarotoxin peptides afford a synthetic vaccine against toxin poisoning, J. Prot. Chem., 13, 490-493, 1994.
244. Atassi, M. Z., Dolimbek, B. Z., and Manshouri, T., Antibody and T-cell recognition of α-bungarotoxin and its synthetic loop peptides, Mol. Immunol., 13, 927-932, 1995.
245. Atassi, M. Z. and Dolimbek, B. Z., Regions of interaction between nicotinic acetylcholine receptor and α-neurotoxins and development of a synthetic vaccine against toxin poisoning, in Methods of Protein Structure Analysis, Atassi, M. Z. and Appella, E., Eds., Plenum Press, New York, 1995, 311-326.
246. Dolimbek, B. Z. and Atassi, M. Z., Protection against α-bungarotoxin poisoning by immunization with synthetic toxin peptides, Mol. Immunol., 33, 681-689, 1996.
247. Atassi, M. Z., Dolimbek, B. Z., Hayakari, M., Middlebrook, J. L., Whitney, B., and Oshima, M., Mapping of the antibody-binding regions on botulinum neurotoxin H-chain domain 855 to 1296 with anti-toxin antibodies from three host species, J. Prot. Chem., 15, 691-700, 1996.
248. Metzger, J. F. and Lewis, G., Jr., Rev. Infect. Dis., 1, 689-690, 1979.
249. Atassi, M. Z., Antigenic structure of myoglobin. The complete immunochemical anatomy of a protein and conclusions relating to antigenic structures of proteins, Immunochemistry, 12, 423-438, 1975.
250. Atassi, M. Z., Precise determination of protein antigenie structures has unraveled the molecular immune recognition of proteins and provided a prototype for synthetic mimicking of other protein binding sites, Mol. Cell. Biochem., 32, 21-44, 1980.
251. Okuda, K., Twining, S. S., Atassi, M. Z., and David, C. S., Genetic control of T-lymphocyte proliferative responses to sperm whale myoglobin and its synthetic antigenic sites in mice, J. Immunol., 121,866-868, 1978.
252. Rosenwasser, L. J., Barcinski, M. A., Schwartz, R. H., and Rosenthal, A. S., Immune response gene control of determinant selection. II. Genetic control of the murine T lymphocyte proliferative response to insulin, J. Immunol., 123, 471-476, 1979.
253. Krco, C. J. and David, C. S., Genetics of immune response: a survey, Crit. Rev. Immunol., 1, 211-257, 1981.
254. Okuda, K., Twining, S. S., David, C. S., and Atassi, M. Z., Genetic control of immune response to sperm whale myoglobin in mice. II. T lymphocyte proliferative response to the synthetic antigenic sites, J. Immunol., 123, 182-188, 1979.
255. Atassi, M. Z., Twining, S. S., Lehmann, H., and David, C. S., Genetic control of the immune response to myoglobin. V. Analysis of the cross-reactivity of 12 myoglobins with sperm whale myoglobin antisera of inbred mouse strains in terms of substitutions in the antigenic sites and in the environmental residues of the sites, Immunol. Commun., 10, 359-365, 1981.
256. David, C. S. and Atassi, M. Z., Genetic control and intersite influences on the immune response to Sperm Whale myoglobin, Adv. Exp. Med. Biol., 150, 97-126, 1982.
257. Rosenberg, J. S., Middlebrook, J. L., and Atassi, M. Z., Localization of the regions on the C-terminal domain of the heavy chain of botulinum toxin A recognized by T-lymphocytes and by antibodies after immunization of mice with pentavalent toxoid, Immunol. Invest., 26, 491-504, 1997.
258. Atassi, M. Z. and Bixler, G. S., Jr., Comparison of the submolecular recognition of proteins by T and B cells, in Vaccines: New Concepts and Developments, Kohler, H. and LoVerde, P. T., Eds., Longman Scientific and Technical, Harlow, England, 1988, 58-70.
259. Atassi, M. Z., Torres, J. V., and Wyde, P. R., Cytotoxic and helper T-lytnphocyte responses to antibody recognition regions on influenza virus hemagglutinin, Adv. Exp. Med. Biol., 251, 49-63, 1989.
260. Gammon, G., Klotz, J., Ando, D., and Sercarz, E. E., The T cell repertoire to a multideterminant antigen. Clonal heterogeneity of the T cell response, variation between syngeneic individuals, and in vitro selection of T cell specificities, J. Immunol., 144, 1571-1577, 1990.
261. C fragment (residues 855 to 1296) of the toxin, Mol. Immunol., 34, 1031-1040, 1997.
262. Oshima, M., Pachner, A. R., and Atassi, M. Z., Profile of the regions of acetylcholine receptor α chain recognized by T-lymphocytes and by antibodies in EAMG-susceptible and nonsusceptible mouse strains after different periods of immunization with the receptor, Mol. Immunol., 31, 833-843, 1994.
263. C, Immunol. Lett., 60, 7-12, 1998.
264. Bixler, G. S., Jr. and Atassi, M. Z., Antigen presentation of myoglobin: profiles of T-cell proliferative responses following priming with synthetic overlapping peptides encompassing the entire protein molecule, Eur. J. Immunol., 15, 917-922, 1985.
265. Bixler, G. S., Jr., Yoshida, T., and Atassi, M. Z., Antigen presentation of lysozyme: T-cell recognition of peptide and intact protein after priming with synthetic overlapping peptides comprising the entire protein chain, Immunology, 56, 103-112, 1985.
266. 1s, J. Immunol., 152, 3711-3719, 1994.
267. Atassi, M. Z., Yokota, S., Twining, S. S., Lehmann, H., and David, C. S., Genetic control of the immune response to myoglobin. VI. Inter-site influences in T-lymphocyte proliferative response from analysis of cross-reactions of ten myoglobins in terms of substitutions in the antigenic sites and in environmental residues of the sites, Mol. Immunol., 18, 961-967, 1981.
268. Rosenberg, J. S., Oshima, M., and Atassi, M. Z., B-cell activation in vitro by helper T cells specific to region α146-162 of Torpedo californica acetylcholine receptor, J. Immunol., 157, 3192-3299, 1996.
269. Hamajima, S. and Atassi, M. Z., B-cell activation in vitro by helper T cells specific to a protein region that is recognized both T cells and by antibodies, Immunol. Invest., 27, 121-134, 1998.
270. Panina-Bordignon, P., Tan, A., Termijtelen, A., Demotz, S., Corradin, G., and Lanzavecehia, A., Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells, Eur. J. Immunol., 19, 2237-2242, 1989.
271. Whelan, S. M., Elmore, M. J., Bodsworth, N. J., Brehm, J. K., Atkinson, T., and Minton, N. P., Molecular cloning of the Clostridium botulinum structural gene encoding the type B neurotoxin and determination of its entire nucleotide sequence, Appl. Env. Microbiol, 58, 2345-2354, 1992.